Intra-articular Injections of Platelet-rich Plasma, Hyaluronic Acid, or Corticosteroids for Knee Osteoarthritis

• Status: Active, not recruiting
• Trial end date: 2021-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess if there are any differences among platelet-rich plasma, hyaluronic acid, and corticosteroid knee intra-articular injection regarding function and pain.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wasit
• Treatments: Hyaluronic Acid; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Patient aged 35-65 years old

• Patient with knee pain that had been continuing for at least 12 months with no relief using anti-inflammatory medications and that deteriorated with weight-bearing

• Knee osteoarthritis that classified as mild-moderate or moderate-severe (Kellgren-Lawrence Grade 2, 3, or 4)

Exclusion Criteria:

• Age > 65 years

• The recent history of knee trauma

• Autoimmune rheumatic diseases

• Accompanying severe hip OA

• Thrombocytopenia or other blood diseases

• Immunosuppressive or anticoagulant treatment

• The invasive procedure applied to the knee

• Intra-articular steroid injection to the knee within the previous 12 months

• Previous joint infection

• Uncontrolled systemic diseases such as diabetes or hypertension, and cancer

• Excessive varus/valgus knee deformity